MLICM
NKTR icon

Metropolitan Life Insurance Company (MetLife)’s Nektar Therapeutics NKTR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-667
Closed -$7.03K – 2495
2023
Q1 		$7.03K Sell
667
-89
-12% -$2.69K ﹤0.01% 2248
2022
Q4 		$25.6K Buy
756
+230
+44% +$11.1K ﹤0.01% 1871
2022
Q3 		$25.2K Sell
526
-209
-28% -$12.4K ﹤0.01% 1899
2022
Q2 		$41.9K Buy
+735
New +$46.4K ﹤0.01% 1610
2022
Q1 		– Sell
-239
Closed -$48.4K – 2533
2021
Q4 		$48.4K Sell
239
-1,990
-89% -$432K ﹤0.01% 2703
2021
Q3 		$600K Sell
2,229
-61
-3% -$14.7K 0.01% 1329
2021
Q2 		$589K Buy
2,290
+5
+0.2% +$1.38K 0.01% 1410
2021
Q1 		$685K Buy
2,285
+148
+7% +$46.1K 0.01% 1211
2020
Q4 		$545K Sell
2,137
-51
-2% -$13.2K 0.01% 1301
2020
Q3 		$545K Sell
2,188
-106
-5% -$33.3K 0.01% 1159
2020
Q2 		$797K Sell
2,294
-895
-28% -$279K 0.01% 879
2020
Q1 		$854K Sell
3,189
-173
-5% -$53.5K 0.02% 756
2019
Q4 		$1.09M Buy
3,362
+1,519
+82% +$440K 0.02% 846
2019
Q3 		$503K Sell
1,843
-398
-18% -$146K 0.01% 1290
2019
Q2 		$1.2M Buy
2,241
+95
+4% +$47.6K 0.02% 796
2019
Q1 		$1.08M Sell
2,146
-48
-2% -$28.4K 0.02% 839
2018
Q4 		$1.08M Buy
2,194
+27
+1% +$16.3K 0.02% 763
2018
Q3 		$1.98M Buy
2,167
+41
+2% +$35K 0.03% 538
2018
Q2 		$1.56M Sell
2,126
-2,333
-52% -$2.69M 0.03% 672
2018
Q1 		$7.11M Buy
4,459
+1,395
+46% +$1.8M 0.1% 159
2017
Q4 		$2.75M Sell
3,064
-3,574
-54% -$2.11M 0.04% 360
2017
Q3 		$2.39M Hold
6,638
– – 0.02% 882
2017
Q2 		$1.95M Buy
6,638
+39
+0.6% +$11.3K 0.01% 953
2017
Q1 		$2.32M Sell
6,599
-143
-2% -$32.1K 0.02% 900
2016
Q4 		$1.24M Buy
6,742
+596
+10% +$121K 0.01% 1189
2016
Q3 		$1.58M Sell
6,146
-53
-0.9% -$13.6K 0.01% 1046
2016
Q2 		$1.32M Hold
6,199
– – 0.01% 1107
2016
Q1 		$1.28M Buy
6,199
+55
+0.9% +$10.6K 0.01% 1065
2015
Q4 		$1.55M Hold
6,144
– – 0.01% 984
2015
Q3 		$1.01M Sell
6,144
-70
-1% -$12.4K 0.01% 1188
2015
Q2 		$1.17M Sell
6,214
-272
-4% -$46.8K 0.01% 1189
2015
Q1 		$1.07M Sell
6,486
-103
-2% -$21.2K 0.01% 1168
2014
Q4 		$1.53M Buy
6,589
+61
+0.9% +$13K 0.01% 1081
2014
Q3 		$1.18M Hold
6,528
– – 0.01% 1183
2014
Q2 		$1.25M Buy
6,528
+38
+0.6% +$6.72K 0.01% 1217
2014
Q1 		$1.18M Buy
6,490
+46
+0.7% +$9.1K 0.01% 1232
2013
Q4 		$1.1M Hold
6,444
– – 0.01% 1265
2013
Q3 		$1.01M Hold
6,444
– – 0.01% 1273
2013
Q2 		$1.12M Buy
+6,444
New +$988K 0.01% 1170

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NKTR Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 667 shares — an estimated $7.03K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NKTR in Q2 2013 and held it in 39 quarters. The position peaked at $7.11M in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 667 Nektar Therapeutics shares in Q2 2023, an estimated $7.03K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Nektar Therapeutics in Q2 2013 and held it in 39 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Nektar Therapeutics position peaked at $7.11M in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.